Stock listing

Stuttgart:RI2 Rigel Pharmaceuticals, Inc. Aktie

German listing (Stuttgart) of Rigel Pharmaceuticals, Inc. · home listing NASDAQ:RIGL

Follow Rigel Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:RIGL

$40.09 USD -2.44 (-5.7%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:RIGL

Past year -8.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$39.62 – $41.66 USDNov 20, 2026
Volume
352,028 sharesNov 20, 2026
Market cap
$754.9M USDAt the close on Nov 20, 2026 · price × 18.83M shares outstanding
52-week range
$24.95 – $52.61 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$11.64M USDMedian day 210,027 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Rigel Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:RIGL · Home$40.09 USD-2.44 (-5.7%)352,028$40.65$41.66$39.62$42.53Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RIGL · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$40.09-2.44-5.7%$40.65$41.66$39.62352,028
$42.53-0.39-0.9%$42.79$43.88$42.03304,827
$42.92-0.81-1.9%$43.43$43.48$42.10242,198
$43.73-0.73-1.6%$44.95$45.70$43.42148,594
$44.46-1.23-2.7%$45.94$45.94$43.84151,587
$45.69+1.17+2.6%$44.21$46.21$43.44325,687
$44.52+0.61+1.4%$44.00$44.63$43.48140,664
$43.91+1.86+4.4%$42.15$44.14$41.91249,582
$42.05+2.40+6.1%$40.39$42.16$39.50310,276
$39.65-6.06-13.3%$41.11$41.67$37.60759,086
$45.71-5.58-10.9%$51.53$51.53$44.99550,900
$51.29+2.43+5.0%$50.57$51.74$49.23288,610
$48.86-1.67-3.3%$50.44$51.29$46.88286,974
$50.53-0.78-1.5%$51.33$51.84$50.00136,045
$51.31-0.14-0.3%$51.80$52.61$50.67174,404
$51.45+0.71+1.4%$51.17$51.60$50.24159,468
$50.74+0.19+0.4%$50.26$51.36$50.06226,326
$50.55+0.64+1.3%$50.09$50.70$49.54133,103
$49.91+1.78+3.7%$48.63$50.00$48.32196,514
$48.13-0.73-1.5%$48.48$48.48$47.47119,260
$48.86-0.020.0%$48.97$49.94$48.55152,640
$48.88+0.77+1.6%$47.64$49.01$47.64195,892
$48.11+1.39+3.0%$46.73$48.16$46.73366,263
$46.72+0.75+1.6%$46.39$47.39$45.48318,414
$45.97-1.28-2.7%$47.58$47.58$45.68141,432
$47.25+0.43+0.9%$47.01$48.52$47.01167,854
$46.82-0.32-0.7%$46.82$47.99$46.37160,104
$47.14-1.67-3.4%$48.70$48.87$47.04133,999
$48.81-0.27-0.6%$49.22$49.89$48.54162,529
$49.08+0.36+0.7%$48.60$50.49$48.60279,362
$48.72+0.73+1.5%$47.33$48.89$46.56216,848
$47.99+1.88+4.1%$45.64$48.15$45.22232,584
$46.11-1.68-3.5%$48.18$48.18$45.93202,598
$47.79+0.64+1.4%$47.02$48.83$46.93391,628
$47.15+0.18+0.4%$47.66$48.00$46.45185,673
$46.97-1.18-2.5%$48.05$48.87$46.81234,998
$48.15-0.74-1.5%$49.27$49.70$47.80252,210
$48.89-0.47-1.0%$49.38$49.70$48.61182,255
$49.36+1.18+2.4%$48.16$49.65$47.49180,879
$48.18+0.29+0.6%$48.23$48.53$47.20204,930
$47.89-0.24-0.5%$47.87$48.14$47.00143,824
$48.13-0.69-1.4%$48.62$48.69$46.91151,375
$48.82+1.73+3.7%$47.50$49.02$47.23242,877
$47.09+0.45+1.0%$47.13$47.51$46.49164,839
$46.64+0.79+1.7%$45.54$46.99$45.24939,569
$45.85+1.37+3.1%$45.25$46.27$45.14165,748
$44.48+0.12+0.3%$44.14$45.37$43.78226,406
$44.36-0.99-2.2%$45.14$46.26$44.22269,889
$45.35-1.89-4.0%$47.32$47.53$44.96335,807
$47.24-0.04-0.1%$47.84$47.86$47.00187,183
$47.28+0.06+0.1%$46.69$47.35$46.28131,329
$47.22-0.15-0.3%$46.85$47.88$46.78177,148
$47.37-1.30-2.7%$48.09$48.11$46.61248,396
$48.67+0.17+0.4%$48.04$48.87$47.77104,968
$48.50-0.92-1.9%$49.51$49.90$48.09190,389
$49.42+1.92+4.0%$48.00$49.70$47.73184,699
$47.50+1.32+2.9%$46.15$47.85$46.15205,505
$46.18-0.30-0.6%$46.04$46.59$45.31243,090
$46.48-0.38-0.8%$46.46$46.79$45.68246,125
$46.86+0.38+0.8%$46.29$47.00$45.61210,027
$46.48-0.27-0.6%$46.34$47.09$45.37232,250
$46.75+1.64+3.6%$45.48$47.46$45.14373,973
$45.11-0.78-1.7%$45.63$46.21$44.51542,005
$45.89+0.64+1.4%$45.74$46.49$45.00322,086
$45.25-1.71-3.6%$46.24$47.34$44.80417,413

Splits

2 splits since 2003 · NASDAQ:RIGL · every price before a split is adjusted for it

DayRatioWhat
1-for-10Consolidation
1-for-9Consolidation
Ticker
Stuttgart:RI2
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Stuttgart
Currency
EUR

What changed lately

Latest news

All Rigel Pharmaceuticals, Inc. news

Rigel Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
25 in the last 12 months · 145 in all · newest Nov 10, 2026 · oldest 2019
Calls
21 calls with a replay · 21 with a transcript · latest Nov 5, 2026
Decks
17 decks · latest Nov 5, 2026

Where Rigel Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:RIGL · Home listingNASDAQUnited StatesUSD
LS Exchange:A40EFYLS ExchangeGermanyEUR
Lang & Schwarz:A40EFYLang & SchwarzGermanyEUR
gettex:RI2gettexGermanyEUR
Tradegate:RI2TradegateGermanyEUR
BX Swiss:RIGLBX SwissSwitzerlandCHF
BOATS:RIGLBOATSUnited StatesUSD
Dusseldorf:RI2DusseldorfGermanyEUR
Frankfurt:RI2FrankfurtGermanyEUR
Munich:RI2MunichGermanyEUR
Stuttgart:RI2 · This pageStuttgartGermanyEUR

Valuation

P/E 2.5× against a median of 11.4×: the lowest of 5 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$663.4M USD
P/E
2.5×
EV/sales
2.3×
EV/EBITDA
8.3×
Price/book
1.7×
Gross margin
89.6%
Operating margin
26.3%
Net margin
106.6%
Debt to equity
0.0×
Beta vs S&P 500
1.02

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Rigel Pharmaceuticals, Inc. · NASDAQ:RIGLUS$754.9MUS$663.4M2.5×2.3×8.3×1.7×106.6%0.0×1.02
Genfleet Therapeutics (Shanghai), Inc. Class H · HKEX:2595US$787.5MUS$518.8Mn/a26.5×n/a3.3×n/a0.0×n/a
Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H · HKEX:2335US$778.7MUS$599.6Mn/an/an/a5.5×n/a0.0×n/a
Ironwood Pharmaceuticals, Inc. · NASDAQ:IRWDUS$778.1MUS$702.9M5.2×1.8×n/an/a37.4%n/a1.16
Syndax Pharmaceuticals, Inc. · NASDAQ:SNDXUS$772.7MUS$695.6Mn/a2.4×n/an/a−72.4%n/a0.64
MeiraGTx Holdings plc · NASDAQ:MGTXUS$766.4MUS$715.6M9.8×1.8×3.7×3.6×19.5%0.6×1.57
ORIC Pharmaceuticals, Inc. · NASDAQ:ORICUS$764.9MUS$503.6Mn/an/an/a2.3×n/a0.0×1.22
Inventiva SA · EURONEXT:IVAUS$760.9MUS$577.3Mn/a117×n/a11.8×n/a1.1×n/a
Obsidian Therapeutics, Inc. · NASDAQ:OBXUS$741.3MUS$530.4M13.0×n/an/a2.3×n/a0.0×n/a
Monte Rosa Therapeutics, Inc. · NASDAQ:GLUEUS$738.3MUS$196.8Mn/a2.8×n/a1.5×−186.2%0.1×0.92
Aimed Bio Inc. · KRX:0009K0US$722.1MUS$653.2M25.2×13.2×34.0×4.8×57.8%0.0×n/a
Median of the othersUS$765.7MUS$588.5M11.4×2.8×18.9×3.4×19.5%0.0×1.16

Forecasts

2 strong buy · 2 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
64.40 USD · Analysts' mean
EPS, year to Dec 2026
3.34 · 4 analysts
Revenue, year to Dec 2026
309.9M · 5 analysts

Team and board

Officers

OfficerRole
Raul R. RodriguezPresident and Chief Executive Officer

Board

DirectorRole
Gregg A. LapointeDirector
Jane WasmanDirector
Kamil Ali-JacksonDirector
Mark W. FrohlichDirector
Michael P. MillerDirector
Raul R. RodriguezPresident and Chief Executive Officer
Walter H. MoosDirector

Events

Calls

CallWhenStatus
Rigel Pharmaceuticals (NASDAQ:RIGL) Q3 2026 Earnings CallThu, Nov 05, 2026 · 4:30 PM ETReplay
Rigel Pharmaceuticals (NASDAQ:RIGL) Q2 2026 Earnings CallTue, Aug 04, 2026 · 4:30 PM ETReplay
Rigel Pharmaceuticals (NASDAQ:RIGL) Q1 2026 Earnings CallTue, May 05, 2026 · 4:30 PM ETReplay
Rigel Pharmaceuticals (NASDAQ:RIGL) Q4 2025 Earnings CallTue, Mar 03, 2026 · 4:30 PM ETReplay
Rigel Pharmaceuticals (NASDAQ:RIGL) Q3 2025 Earnings CallTue, Nov 04, 2025 · 4:30 PM ETReplay
Rigel Pharmaceuticals (NASDAQ:RIGL) Q2 2025 Earnings CallTue, Aug 05, 2025 · 4:30 PM ETReplay
Rigel Pharmaceuticals (NASDAQ:RIGL) Q1 2025 Earnings CallTue, May 06, 2025 · 4:30 PM ETReplay
Rigel Pharmaceuticals (NASDAQ:RIGL) Q4 2024 Earnings CallTue, Feb 04, 2025 · 4:30 PM ETReplay
Rigel Pharmaceuticals (NASDAQ:RIGL) Q3 2024 Earnings CallThu, Nov 07, 2024 · 4:30 PM ETReplay
Rigel Pharmaceuticals (NASDAQ:RIGL) Q2 2024 Earnings CallTue, Aug 06, 2024 · 4:30 PM ETReplay
All 21 calls
CallWhenStatus
Rigel Pharmaceuticals (NASDAQ:RIGL) Q1 2024 Earnings CallTue, May 07, 2024 · 4:30 PM ETReplay
Rigel Pharmaceuticals (NASDAQ:RIGL) Q4 2023 Earnings CallTue, Mar 05, 2024 · 4:30 PM ETReplay
Rigel Pharmaceuticals (NASDAQ:RIGL) Q3 2023 Earnings CallTue, Nov 07, 2023 · 4:30 PM ETReplay
Rigel Pharmaceuticals (NASDAQ:RIGL) Q2 2023 Earnings CallTue, Aug 01, 2023 · 4:30 PM ETReplay
Rigel Pharmaceuticals (NASDAQ:RIGL) Q1 2023 Earnings CallTue, May 02, 2023 · 4:30 PM ETReplay
Rigel Pharmaceuticals (NASDAQ:RIGL) Q3 2022 Earnings CallThu, Nov 03, 2022 · 4:30 PM ETReplay
Rigel Pharmaceuticals (NASDAQ:RIGL) Q2 2022 Earnings CallTue, Aug 02, 2022 · 4:30 PM ETReplay
Rigel Pharmaceuticals (NASDAQ:RIGL) Q1 2022 Earnings CallTue, May 03, 2022 · 4:30 PM ETReplay
Rigel Pharmaceuticals (NASDAQ:RIGL) Q4 2021 Earnings CallTue, Mar 01, 2022 · 4:30 PM ETReplay
Rigel Pharmaceuticals (NASDAQ:RIGL) Q3 2021 Earnings CallTue, Nov 02, 2021 · 4:30 PM ETReplay
Rigel Pharmaceuticals (NASDAQ:RIGL) Q2 2021 Earnings CallTue, Aug 03, 2021 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 5, 2026 · After close−13.3%
Q2 2026Aug 4, 2026 · After close+4.6%
Q1 2026May 5, 2026 · After close−5.1%
Q4 2025Mar 4, 2026−10.6%
Q3 2025Nov 4, 2025 · After close+33.4%
Q2 2025Aug 5, 2025 · After close+23.0%
Q1 2025May 6, 2025 · After close+1.1%
Q4 2024Mar 4, 2025 · After close−8.1%
Q3 2024Nov 7, 2024 · After close+42.9%
Q2 2024Aug 6, 2024 · After close+5.8%
All 20 quarters
QuarterResultsShare move
Q1 2024May 7, 2024 · After close−16.6%
Q4 2023Mar 5, 2024 · After close+5.4%
Q3 2023Nov 7, 2023 · After close+2.2%
Q2 2023Aug 1, 2023 · After close−3.0%
Q1 2023May 2, 2023 · After close+0.9%
Q4 2022Mar 7, 2023 · After close+21.8%
Q3 2022Nov 3, 2022 · After close+2.0%
Q2 2022Aug 2, 2022 · After close+8.5%
Q1 2022May 3, 2022 · After close+6.5%
Q4 2021Mar 1, 2022 · After close+21.1%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck65 slidesNov 5, 2026
H.C. Wainwright 28th Annual Global Investment Conference (September 2026)Conference40 slidesSep 15, 2026
Cantor Global Healthcare Conference 2026Conference40 slidesSep 10, 2026
Investor Presentation (August 2026)Investor deck72 slidesAug 13, 2026
Q2 2026 Earnings PresentationEarnings45 slidesAug 4, 2026
Q2 2026 Earnings PresentationEarnings73 slidesAug 4, 2026
Q1 2026 Earnings PresentationEarnings51 slidesMay 5, 2026
Q4 2025 Earnings PresentationEarnings54 slidesMar 3, 2026
Q1 2025 Earnings PresentationEarnings38 slidesMay 6, 2025
Q4 2024 Earnings PresentationEarnings40 slidesFeb 4, 2025
All 17 decks
DeckKindSlidesDate
Q3 2024 Earnings PresentationEarnings37 slidesNov 7, 2024
Q2 2024 Earnings PresentationEarnings38 slidesAug 6, 2024
Q1 2024 Earnings PresentationEarnings43 slidesMay 7, 2024
Q4 2023 Earnings PresentationEarnings37 slidesMar 5, 2024
Q3 2023 Earnings PresentationEarnings30 slidesNov 7, 2023
Technical Presentation (October 2016)Technical26 slidesOct 20, 2016
Technical Presentation (December 2007)Technical9 slidesDec 4, 2007

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue294.3M179.3M116.9M120.2M149.2M108.6M59.3M44.5M4.48M20.4M
Cost of revenue19.6M18.6M7.11M1.75M1.08M895.0K906.0K287.0K46.3M63.4M
Gross profit274.7M160.6M109.8M118.5M148.2M107.7M58.4M44.2M-41.8M-43.1M
Research and development33.3M23.4M24.5M60.3M65.2M60.1M52.9M46.9M46.3M63.4M
Selling, general and administrative115.9M113.1M105.7M112.5M91.9M76.6M74.6M70.0M37.8M20.9M
Operating income125.5M24.2M-20.5M-55.5M-12.5M-29.0M-69.1M-72.7M-79.6M-69.7M
Depreciation and amortization2.42M2.23M1.24M998.0K1.16M706.0K683.0K594.0K465.0K941.0K
EBITDA127.9M26.4M-19.3M-54.6M-11.3M-28.3M-68.4M-72.1M-79.2M-68.8M
Interest expense7.32M7.92M6.87M3.71M4.86M1.35M335.0K000
Income before tax121.8M18.4M-25.1M-58.6M-17.3M-29.7M-66.9M-70.5M-78.0M-69.2M
Income tax-245.2M881.0K03.02M605.0K647.0K-348.0K000
Net income367.0M17.5M-25.1M-58.6M-17.9M-29.7M-66.9M-70.5M-78.0M-69.2M
Earnings per share, basic20.400.99-1.44-3.44-0.11-0.18-0.40-0.44-0.62-0.73
Earnings per share, diluted19.480.99-1.44-3.44-0.11-0.18-0.40-0.44-0.62-0.73

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents40.6M56.7M32.8M24.5M18.9M30.4M22.5M76.3M38.3M17.6M
Short-term investments114.4M20.6M24.1M33.7M106.1M27.0M75.6M52.2M77.5M57.1M
Receivables51.8M41.6M30.6M40.3M15.5M16.0M10.1M4.08M00
Inventory11.5M6.00M5.52M9.12M6.62M1.64M1.35M894.0K00
Current assets240.2M135.1M99.3M115.9M154.5M89.0M119.0M137.0M117.4M76.2M
Property, plant and equipment30.0K92.0K165.0K857.0K2.18M2.68M2.16M1.39M875.0K1.16M
Goodwill00
Total assets513.6M164.0M117.2M134.3M167.3M110.4M147.6M139.1M119.1M78.1M
Accounts payable7.19M3.34M7.14M22.5M3.79M3.71M4.15M6.39M2.64M5.56M
Current liabilities99.2M63.3M53.3M65.2M63.6M40.8M58.2M27.7M18.3M22.6M
Long-term debt22.5M52.4M52.4M39.4M19.9M19.8M9.81M00
Total debt52.5M60.0M60.0M40.0M20.0M20.0M10.0M284.0K3.46M
Total liabilities122.1M160.7M145.9M147.9M137.0M76.4M93.8M29.2M18.5M23.1M
Shareholders' equity391.5M3.29M-28.6M-13.6M30.4M34.0M53.8M109.9M100.6M55.0M
Shares outstanding18.3M17.7M17.5M173.4M171.6M169.3M168.0M167.2M146.8M99.3M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations75.7M31.5M-5.74M-73.8M5.88M-52.2M-41.5M-58.8M-77.6M-75.9M
Capital spending0-396.0K-15.0M-450.0K-627.0K-1.26M-1.46M-1.11M-164.0K-804.0K
Free cash flow75.7M31.1M-20.7M-74.2M5.25M-53.4M-43.0M-59.9M-77.7M-76.7M
Cash from investing-92.4M4.13M-4.30M72.8M-80.0M47.5M-23.7M25.0M-19.5M24.9M
Cash from financing601.0K-11.6M18.4M6.55M62.7M12.6M11.4M71.9M117.7M25.2M
Dividends paid00
Share buybacks0-10.0M02.12M4.78M2.60M1.58M71.9M117.7M25.2M
Change in cash-16.1M24.0M8.33M5.57M-11.5M7.85M-53.8M38.0M20.7M-25.8M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 13, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 10, 2026Big-stake noticeSEC
8-K · Current reportNov 5, 2026ResultsSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
4 · Change in ownershipSep 3, 2026Insider tradeSEC
4 · Change in ownershipSep 3, 2026Insider tradeSEC
4 · Change in ownershipSep 3, 2026Insider tradeSEC
4 · Change in ownershipSep 3, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansAug 4, 2026Offer documentSEC
8-K · Current reportAug 4, 2026ResultsSEC
10-Q · Quarterly reportAug 4, 2026Quarterly reportSEC
4 · Change in ownershipJul 10, 2026Insider tradeSEC
8-K · Current reportJul 1, 2026Management or board changeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
144 · Notice of proposed saleJun 22, 2026Other filingsSEC
8-K · Current reportJun 17, 2026Acquisition or disposalSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipMay 28, 2026Insider tradeSEC
144 · Notice of proposed saleMay 26, 2026Other filingsSEC
8-K · Current reportMay 20, 2026Management or board changeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
8-K · Current reportMay 12, 2026Material contractSEC
SCHEDULE 13G · Big-stake noticeMay 7, 2026Big-stake noticeSEC
8-K · Current reportMay 5, 2026ResultsSEC
10-Q · Quarterly reportMay 5, 2026Quarterly reportSEC
8-K · Current reportApr 21, 2026Current reportSEC
DEFA14A · Additional proxy materialApr 3, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 3, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 27, 2026Big-stake noticeSEC
8-K · Current reportMar 3, 2026ResultsSEC
10-K · Annual reportMar 3, 2026Annual reportSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 20, 2026Other filingsSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 9, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 3, 2026Insider tradeSEC
8-K · Current reportFeb 3, 2026Management or board changeSEC
8-K · Current reportJan 12, 2026ResultsSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
8-K · Current reportDec 10, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
8-K · Current reportNov 4, 2025ResultsSEC
10-Q · Quarterly reportNov 4, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 7, 2025Big-stake noticeSEC
4 · Change in ownershipSep 17, 2025Insider tradeSEC
4 · Change in ownershipSep 17, 2025Insider tradeSEC
4 · Change in ownershipSep 17, 2025Insider tradeSEC
4 · Change in ownershipSep 17, 2025Insider tradeSEC
4 · Change in ownershipSep 17, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
S-8 · Registration statement for employee plansAug 6, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 5, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 5, 2025Quarterly reportSEC
8-K · Current reportAug 5, 2025ResultsSEC
4 · Change in ownershipMay 28, 2025Insider tradeSEC
4 · Change in ownershipMay 28, 2025Insider tradeSEC
4 · Change in ownershipMay 28, 2025Insider tradeSEC
4 · Change in ownershipMay 28, 2025Insider tradeSEC
4 · Change in ownershipMay 28, 2025Insider tradeSEC
4 · Change in ownershipMay 28, 2025Insider tradeSEC
8-K · Current reportMay 23, 2025Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
8-K · Current reportMay 6, 2025ResultsSEC
10-Q · Quarterly reportMay 6, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 17, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersApr 10, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 10, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 10, 2025Meeting noticeSEC
8-K · Current reportMar 27, 2025Current reportSEC
4 · Change in ownershipMar 19, 2025Insider tradeSEC
4 · Change in ownershipMar 19, 2025Insider tradeSEC
4 · Change in ownershipMar 19, 2025Insider tradeSEC
4 · Change in ownershipMar 19, 2025Insider tradeSEC
4 · Change in ownershipMar 19, 2025Insider tradeSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
3 · Initial statement of ownershipMar 10, 2025Insider tradeSEC
8-K · Current reportMar 10, 2025Management or board changeSEC
8-K · Current reportMar 4, 2025ResultsSEC
10-K · Annual reportMar 4, 2025Annual reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 11, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 7, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 6, 2025Insider tradeSEC
4 · Change in ownershipFeb 6, 2025Insider tradeSEC
4 · Change in ownershipFeb 6, 2025Insider tradeSEC
4 · Change in ownershipFeb 6, 2025Insider tradeSEC
144 · Notice of proposed saleFeb 5, 2025Other filingsSEC
144 · Notice of proposed saleFeb 5, 2025Other filingsSEC
144 · Notice of proposed saleFeb 5, 2025Other filingsSEC
144 · Notice of proposed saleFeb 5, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeFeb 5, 2025Big-stake noticeSEC
144 · Notice of proposed saleFeb 4, 2025Other filingsSEC
144 · Notice of proposed saleFeb 4, 2025Other filingsSEC
144 · Notice of proposed saleFeb 4, 2025Other filingsSEC
144 · Notice of proposed saleFeb 4, 2025Other filingsSEC
4 · Change in ownershipJan 31, 2025Insider tradeSEC
4 · Change in ownershipJan 31, 2025Insider tradeSEC
4 · Change in ownershipJan 31, 2025Insider tradeSEC
4 · Change in ownershipJan 31, 2025Insider tradeSEC
4 · Change in ownershipJan 31, 2025Insider tradeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
144 · Notice of proposed saleJan 24, 2025Other filingsSEC
8-K · Current reportJan 13, 2025ResultsSEC
8-K · Current reportDec 9, 2024Current reportSEC
4 · Change in ownershipNov 26, 2024Insider tradeSEC
4 · Change in ownershipNov 26, 2024Insider tradeSEC
4 · Change in ownershipNov 26, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
8-K · Current reportNov 7, 2024ResultsSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportSep 19, 2024Management or board changeSEC
4 · Change in ownershipSep 4, 2024Insider tradeSEC
4 · Change in ownershipSep 4, 2024Insider tradeSEC
8-K · Current reportSep 3, 2024Material contractSEC
EFFECT · Notice that a registration is effectiveAug 12, 2024Other filingsSEC
CORRESP · Letter to the SECAug 8, 2024Other filingsSEC
UPLOAD · Letter from the SECAug 7, 2024Other filingsSEC
S-8 · Registration statement for employee plansAug 6, 2024Offer documentSEC
8-K · Current reportAug 6, 2024ResultsSEC
10-Q · Quarterly reportAug 6, 2024Quarterly reportSEC
S-3 · Registration statementAug 2, 2024Offer documentSEC
8-K · Current reportJun 27, 2024Current reportSEC
8-K · Current reportJun 25, 2024Current reportSEC
4 · Change in ownershipMay 29, 2024Insider tradeSEC
4 · Change in ownershipMay 29, 2024Insider tradeSEC
4 · Change in ownershipMay 29, 2024Insider tradeSEC
4 · Change in ownershipMay 29, 2024Insider tradeSEC
4 · Change in ownershipMay 29, 2024Insider tradeSEC
4 · Change in ownershipMay 29, 2024Insider tradeSEC
8-K · Current reportMay 29, 2024Management or board changeSEC
8-K · Current reportMay 7, 2024ResultsSEC
10-Q · Quarterly reportMay 7, 2024Quarterly reportSEC
8-K · Current reportApr 12, 2024Material contractSEC
ARS · Annual report to shareholdersApr 10, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 10, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 10, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementMar 29, 2024Meeting noticeSEC
4 · Change in ownershipMar 29, 2024Insider tradeSEC
3 · Initial statement of ownershipMar 29, 2024Insider tradeSEC
8-K · Current reportMar 5, 2024ResultsSEC
10-K · Annual reportMar 5, 2024Annual reportSEC
4 · Change in ownershipMar 1, 2024Insider tradeSEC
4 · Change in ownershipMar 1, 2024Insider tradeSEC
4 · Change in ownershipMar 1, 2024Insider tradeSEC
4 · Change in ownershipMar 1, 2024Insider tradeSEC
8-K · Current reportFeb 22, 2024Acquisition or disposalSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 9, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 6, 2024Insider tradeSEC
4 · Change in ownershipFeb 6, 2024Insider tradeSEC
4 · Change in ownershipFeb 6, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 5, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 2, 2024Big-stake noticeSEC
4 · Change in ownershipJan 25, 2024Insider tradeSEC
4 · Change in ownershipJan 25, 2024Insider tradeSEC
4 · Change in ownershipJan 25, 2024Insider tradeSEC
4 · Change in ownershipJan 25, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedJan 25, 2024Big-stake noticeSEC
8-K · Current reportJan 8, 2024ResultsSEC
8-K · Current reportNov 30, 2023Current reportSEC
8-K · Current reportNov 7, 2023ResultsSEC
10-Q · Quarterly reportNov 7, 2023Quarterly reportSEC
S-8 · Registration statement for employee plansAug 1, 2023Offer documentSEC

This page holds 200 of 1,000 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Rigel Pharmaceuticals, Inc.’s releases · as of Nov 2, 2026

Common shares
18,829,972
Fully diluted
18,829,972

Fully diluted

LineSharesAs of
Common shares18,829,972Nov 2, 2026

Share count over time

CountShares
Nov 2, 202618,829,972

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
BlackRock2.07M11.0%US$99.5MSep 30, 2026
Soleus Capital Management, L.P.1.84M9.8%US$88.8MSep 30, 2026
Armistice Capital, LLC1.54M8.2%US$74MSep 30, 2026
Morgan Stanley1.26M6.7%US$60.5MSep 30, 2026
Vanguard1.14M6.1%US$55.1MSep 30, 2026
American Century1.04M5.5%US$50.3MSep 30, 2026
State Street880K4.7%US$42.4MSep 30, 2026
Lsv Asset Management787K4.2%US$37.9MSep 30, 2026
Assenagon Asset Management S.A.536K2.8%US$25.8MSep 30, 2026
Geode Capital483K2.6%US$23.3MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Acadian Asset Management LLC462K2.5%US$22.3MSep 30, 2026
D. E. Shaw & Co., Inc.453K2.4%US$21.8MSep 30, 2026
Marshall Wace, LLP403K2.1%US$19.4MSep 30, 2026
Legal & General256K1.4%US$12.3MSep 30, 2026
CM Management, LLC250K1.3%US$12MSep 30, 2026
Goldman Sachs229K1.2%US$11MSep 30, 2026
Nomura195K1.0%US$9.39MSep 30, 2026
AQR Capital Management LLC182K0.97%US$8.78MSep 30, 2026
UBS180K0.96%US$8.67MSep 30, 2026
Schwab166K0.88%US$8MSep 30, 2026
O'Shaughnessy Asset Management, LLC148K0.79%US$7.6MSep 30, 2026
Northern Trust145K0.77%US$6.97MSep 30, 2026
Franklin Templeton144K0.76%US$7.39MSep 30, 2026
Bridgeway Capital Management, LLC131K0.69%US$6.29MSep 30, 2026
Globeflex Capital L P113K0.60%US$5.43MSep 30, 2026
Ritholtz Wealth Management108K0.57%US$5.18MSep 30, 2026
BNY107K0.57%US$5.17MSep 30, 2026
Dimensional101K0.53%US$4.85MSep 30, 2026
First Trust98,9340.53%US$4.76MSep 30, 2026
Hennion & Walsh Asset Management, Inc.90,8240.48%US$4.37MSep 30, 2026
HSBC88,4360.47%US$4.31MSep 30, 2026
Empowered Funds, LLC85,7350.46%US$4.13MSep 30, 2026
Healthcare Of Ontario Pension Plan Trust Fund80,0000.42%US$3.85MSep 30, 2026
Bank of America79,7850.42%US$3.84MSep 30, 2026
Credit Agricole S A78,1640.42%US$3.76MSep 30, 2026
Renaissance Technologies73,1190.39%US$3.52MSep 30, 2026
Lionhunter Capital Management, LLC70,0450.37%US$3.37MSep 30, 2026
Wellington64,2120.34%US$3.09MSep 30, 2026
Universal- Beteiligungs- und Servicegesellschaft mbH56,5780.30%US$2.72MSep 30, 2026
Principal56,1790.30%US$2.71MSep 30, 2026
OMERS ADMINISTRATION Corp51,9000.28%US$2.5MSep 30, 2026
Virtus Investment Advisers, LLC51,3090.27%US$2.47MSep 30, 2026
Burney Co/50,8510.27%US$2.45MSep 30, 2026
Nuveen50,6130.27%US$2.44MSep 30, 2026
Segall Bryant & Hamill, LLC45,8780.24%US$2.21MSep 30, 2026
Sterling Capital Management LLC45,7000.24%US$2.2MSep 30, 2026
JPMorgan43,8700.23%US$2.14MSep 30, 2026
State Board Of Administration Of Florida Retirement System43,8180.23%US$2.11MSep 30, 2026
Raymond James Financial Inc39,4020.21%US$1.9MSep 30, 2026
Alps Advisors Inc37,5180.20%US$1.81MSep 30, 2026

This page holds 50 of 165 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF650K3.5%US$25.4MJun 30, 2026
Avantis U.S. Small Cap Value ETF595K3.2%US$18.1MMay 31, 2026
Vanguard Total Stock Market Index Fund556K3.0%US$21.7MJun 30, 2026
iShares Russell 2000 ETF482K2.6%US$18.9MJun 30, 2026
Vanguard Extended Market Index Fund212K1.1%US$8.31MJun 30, 2026
Fidelity Small Cap Index Fund201K1.1%US$7.42MJul 31, 2026
iShares Russell 2000 Value ETF172K0.92%US$6.75MJun 30, 2026
Nomura Healthcare Fund160K0.85%US$6.26MJun 30, 2026
iShares Biotechnology ETF126K0.67%US$4.94MJun 30, 2026
Fidelity Extended Market Index Fund94,1150.50%US$2.87MMay 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Vanguard Russell 2000 Index Fund91,9130.49%US$2.8MMay 31, 2026
Fidelity Enhanced Small Cap Core ETF91,8880.49%US$3.59MJun 30, 2026
BlackRock Advantage Small Cap Core Fund90,8580.48%US$2.77MMay 29, 2026
Schwab U.S. Small-Cap ETF89,3590.47%US$2.72MMay 31, 2026
Pacer US Small Cap Cash Cows 100 ETF84,7900.45%US$3.12MJul 31, 2026
EA Bridgeway Omni Small-Cap Value ETF79,1840.42%US$3.1MJun 30, 2026
LSV Small Cap Value Fund73,7000.39%US$2.71MJul 31, 2026
Inspire Fidelis Multi Factor ETF70,9110.38%US$2.16MMay 31, 2026
iShares Micro-Cap ETF61,4940.33%US$2.41MJun 30, 2026
First Trust Dow Jones Select MicroCap Index Fund61,4050.33%US$2.4MJun 30, 2026
Principal U.S. Small-Cap ETF50,9720.27%US$1.99MJun 30, 2026
Omni Small-Cap Value Fund45,0000.24%US$1.76MJun 30, 2026
Schwab Small-Cap Index Fund44,6510.24%US$1.64MJul 31, 2026
Virtus Biotech Etf41,3130.22%US$1.52MJul 31, 2026
AQR Small Cap Multi-Style Fund40,3560.21%US$1.58MJun 30, 2026
American Beacon Small Cap Value Fund39,4720.21%US$1.45MJul 31, 2026
iShares Genomics Immunology and Healthcare ETF38,8070.21%US$1.43MJul 31, 2026
Avantis U.S. Small Cap Value Fund36,7780.20%US$1.12MMay 31, 2026
Optimum Small-Mid Cap Value Fund35,0000.19%US$1.37MJun 30, 2026
Master Small Cap Index Series34,3940.18%US$1.35MJun 30, 2026
Fidelity Total Market Index Fund33,5310.18%US$1.02MMay 31, 2026
Vanguard U.S. Multifactor ETF32,9190.17%US$1MMay 31, 2026
Dimensional U.S. Small Cap ETF32,6590.17%US$1.2MJul 31, 2026
U.S. Micro Cap Portfolio32,2380.17%US$1.19MJul 31, 2026
Tax-Managed U.S. Mid & Small Cap Fund29,9340.16%US$1.1MJul 31, 2026
Strategic Advisers U.S. Total Stock Fund29,2150.16%US$891KMay 31, 2026
JPMorgan Diversified Return U.S. Small Cap Equity ETF29,1240.15%US$1.07MJul 31, 2026
MFS Blended Research Small Cap Equity Fund28,4250.15%US$867KMay 31, 2026
Fidelity Series Total Market Index Fund27,5940.15%US$841KMay 31, 2026
Vanguard U.S. Momentum Factor ETF27,5490.15%US$840KMay 31, 2026
Fidelity Small Cap Value Index Fund25,7410.14%US$1.01MJun 30, 2026
Nuveen Small Cap Blend Index Fund24,4620.13%US$900KJul 31, 2026
Goldman Sachs ActiveBeta(R) U.S. Small Cap Equity ETF23,7730.13%US$725KMay 31, 2026
Vanguard U.S. Value Factor ETF22,7210.12%US$693KMay 31, 2026
iShares Core S&P Total U.S. Stock Market ETF22,6630.12%US$887KJun 30, 2026
Direxion Daily S&P Biotech Bull 3X Shares22,0930.12%US$813KJul 31, 2026
SIMT Tax-Managed Small/Mid Cap Fund21,4690.11%US$840KJun 30, 2026
Nuveen Equity Index Fund20,8110.11%US$766KJul 31, 2026
Avantis U.S. Small Cap Equity ETF20,7870.11%US$634KMay 31, 2026
EQ/2000 Managed Volatility Portfolio19,9460.11%US$780KJun 30, 2026

This page holds 50 of 195 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Ali-Jackson Kamil
Director
Sale2,500USD 35.00US$87,500Jun 22, 2026
Ali-Jackson Kamil
Director
Sale2,500USD 29.17US$72,925May 26, 2026

Big stakes

StakeStakeSharesDateFiling
Soleus Capital Master Fund, L.P.9.90%1.84MJun 30, 2026Schedule 13G
Armistice Capital, LLC8.22%1.54MSep 30, 2026Schedule 13G
BlackRock, Inc.7.70%1.38MMar 31, 2025Schedule 13G
Morgan Stanley6.50%1.21MSep 30, 2026Schedule 13G
American Century Investment Management, Inc.5.60%1.04MSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Stephen A. Sherwin
Other companies: Biogen Inc. (Director · Since at least Mar 20, 2010); Neurocrine Biosciences, Inc. (Director · Since at least Jun 30, 2006); Epiphany Technology Acquisition Corp (Director · Sep 16, 2022 – Sep 16, 2022 · Past); BioPlus Acquisition Corp (Director · Dec 2, 2021 – Dec 2, 2021 · Past); Aduro Biotech Inc (Director · Jun 25, 2015 – May 5, 2020 · Past); Vical Incorporated (Director · May 23, 2013 – May 21, 2015 · Past); Verastem, Inc. (Director · Mar 5, 2013 – Jun 12, 2015 · Past); ANI Pharmaceuticals, Inc. (Director · Oct 14, 2009 – Mar 30, 2012 · Past); Cell Genesys Inc (Chairman and CEO, Director · Feb 7, 2006 – Oct 14, 2009 · Past)
Director · May 31, 2006 – May 11, 2016 · Past
Gary A. Lyons
Other companies: Travere Therapeutics, Inc. (Director · Since at least Oct 8, 2014); Neurocrine Biosciences, Inc. (Director · Since at least May 25, 2010); Brickell Biotech Inc (Director · Feb 14, 2020 – May 17, 2022 · Past); Eledon Pharmaceuticals, Inc. (Director · May 10, 2017 – May 1, 2023 · Past); Humanigen Inc (Director · Aug 10, 2012 – Jul 10, 2015 · Past); NeurogesX Inc (Director · Apr 27, 2011 – Jun 7, 2012 · Past); Vical Incorporated (Director · May 25, 2010 – May 23, 2018 · Past); Facet Biotech Corp (Director · Apr 20, 2010 – Apr 21, 2010 · Past)
Director · May 28, 2010 – May 26, 2023 · Past
Hollings Renton
Other companies: AnaptysBio, Inc. (Chair of the Nominating and Corporate Governance Committee · Since at least Jan 25, 2017); Zymeworks Inc. (Director · Jan 1, 2019 – Dec 7, 2023 · Past); Kythera Biopharmaceuticals Inc (Director · Dec 31, 2014 – Oct 1, 2015 · Past); Portola Pharmaceuticals Inc (Director · May 21, 2013 – Jul 2, 2020 · Past); Affymax Inc (Director · Jun 9, 2009 – Jun 13, 2012 · Past); Cepheid (Director · Apr 27, 2006 – Nov 4, 2016 · Past); Onyx Pharmaceuticals Inc (President and CEO, Director · Jan 19, 2006 – Feb 19, 2008 · Past)
Director · May 31, 2006 – May 15, 2013 · Past
Keith A. Katkin
Other companies: Emergent BioSolutions Inc. (Independent Director · Since at least Apr 1, 2022); Eledon Pharmaceuticals, Inc. (Chairman of the Board of Directors · Since at least May 10, 2017); Syndax Pharmaceuticals, Inc. (Director · Since at least Mar 29, 2017); Urovant Sciences Ltd (PEO;CEO/Urovant Sciences, Inc., Director · Sep 26, 2018 – Feb 19, 2020 · Past); Carbylan Therapeutics Inc (Director · Apr 8, 2015 – Aug 3, 2015 · Past); Avanir Pharmaceuticals Inc (President and CEO, Director · May 15, 2013 – Dec 15, 2014 · Past)
Director · Jun 29, 2015 – May 19, 2021 · Past
Anthony Gregg Lapointe
Other companies: Astria Therapeutics Inc (Director · Since at least Jan 3, 2019); Soligenix, Inc. (Director · Since at least Mar 10, 2009); Raptor Pharmaceutical Corp (Director · Jan 1, 2015 – Oct 24, 2016 · Past); Questcor Pharmaceuticals Inc (Director · Oct 9, 2009 – Jan 1, 2010 · Past); SciClone Pharmaceuticals Inc (Director · Mar 30, 2009 – Oct 13, 2017 · Past)
Director · Since at least Oct 31, 2017
Michael P. Miller
Other companies: BioXcel Therapeutics, Inc. (Director · Since at least Jul 1, 2022); Puma Biotechnology Inc (Director · Since at least Feb 23, 2018); Jazz Pharmaceuticals plc (EVP, US Commercial · Jul 31, 2014 – Mar 12, 2020 · Past); VIVUS Inc (Chief Commercial Officer · Apr 26, 2010 – Jan 25, 2013 · Past)
Director · Since at least Feb 1, 2026
Jean Deleage
Other companies: Raptor Pharmaceutical Corp (Director · Oct 3, 2006 – Jun 19, 2008 · Past); Idm Pharma Inc (Director · Jun 14, 2006 – Jun 14, 2007 · Past); Kosan Biosciences Inc (Director · May 5, 2006 – Jun 26, 2008 · Past)
Director · May 31, 2006 – May 28, 2010 · Past
Ryan Maynard
Other companies: Foghorn Therapeutics Inc. (Chief Financial Officer · Since at least Feb 23, 2026); Iovance Biotherapeutics, Inc. (Director · Since at least Feb 16, 2015); Tvardi Therapeutics, Inc. (CHIEF FINANCIAL OFFICER · Sep 12, 2022 – Feb 8, 2024 · Past)
EVP & CFO · May 27, 2010 – Nov 3, 2017 · Past
Alison L Hannah
Other companies: NeoGenomics, Inc. (Director · Since at least Jun 12, 2015); CytomX Therapeutics, Inc. (Chief Medical Officer · Feb 3, 2020 – Jul 19, 2022 · Past)
EVP, Chief Medical Officer · Since at least May 14, 2021
Anne-Marie Duliege
Other companies: ChemoCentryx Inc. (EVP, Chief of Strategic Dev. · Mar 25, 2014 – Nov 18, 2014 · Past); Affymax Inc (Chief Medical Officer · Jan 1, 2008 – Jan 30, 2013 · Past)
EVP & Chief Medical Officer · Mar 7, 2016 – Mar 20, 2019 · Past
All 33 people
PersonSeat
Jane Wasman
Other companies: SELLAS Life Sciences Group, Inc. (Director · Since at least Dec 29, 2017); Acorda Therapeutics Inc (President, Intl and GC · Feb 9, 2006 – Dec 2, 2019 · Past)
Director · Since at least Apr 1, 2019
Kamil Ali-Jackson
Other companies: PDS Biotechnology Corporation (Director · Since at least Jun 15, 2021); Aclaris Therapeutics, Inc. (Chief Legal Officer · Dec 15, 2020 – Jan 3, 2022 · Past)
Director · Since at least Dec 16, 2021
Mark W. Frohlich
Other companies: Juno Therapeutics Inc (See Remarks · Dec 18, 2014 – Feb 29, 2016 · Past); Dendreon Corp (EVP, R&D and CMO · Apr 3, 2013 – Jan 20, 2014 · Past)
Director · Since at least Mar 6, 2025
Peter S Ringrose
Other companies: Theravance Biopharma, Inc. (Director · May 14, 2014 – Apr 30, 2019 · Past); Innoviva, Inc. (Director · Apr 27, 2010 – May 22, 2014 · Past)
Director · May 28, 2010 – May 17, 2018 · Past
Wolfgang Dummer
Other companies: Alpine Immune Sciences Inc (Chief Medical Officer · Oct 2, 2023 – Oct 2, 2023 · Past); Aridis Pharmaceuticals Inc. (Chief Medical Officer · Aug 13, 2018 – Dec 5, 2018 · Past)
EVP & CMO · Nov 4, 2019 – Feb 2, 2023 · Past
Brian L Kotzin
Other companies: Kyverna Therapeutics, Inc. (Director · Feb 7, 2024 – Feb 7, 2024 · Past)
Director · Aug 21, 2017 – May 25, 2024 · Past
Eldon C Mayer III
Other companies: Eiger Biopharmaceuticals Inc (Ex VP & Chief Commerc. Officer · Jan 5, 2018 – Mar 17, 2023 · Past)
EVP & Chief Commercial Officer · Oct 10, 2016 – Nov 18, 2019 · Past
Gregg A. Lapointe
Other companies: Soligenix, Inc. (Board Director · Since at least Nov 5, 2026)
Director · Since at least Nov 5, 2026
James M Gower
Other companies: Cell Genesys Inc (Director · Jun 30, 2006 – Oct 14, 2009 · Past)
CEO & Board Chairman, Director · Jan 25, 2006 – Feb 27, 2014 · Past
Stacy Markel
Other companies: Nuvation Bio Inc. (Chief People Officer · Since at least Feb 10, 2021)
EVP Human Resources · Mar 19, 2018 – Mar 20, 2019 · Past
Bradford S GoodwinDirector · May 15, 2013 – May 19, 2021 · Past
David A SantosEVP, Chief Commercial Officer · Since at least Jan 27, 2021
Dean L SchornoEVP & Chief Financial Officer · Since at least Jan 23, 2024
Dolly VanceEVP Corp. Affairs, G.C., Sect. · Mar 30, 2009 – Sep 14, 2022 · Past
Donald G PayanEVP, Pres. Discovery&Research, Director · Apr 4, 2016 – Aug 30, 2016 · Past
Elliott B GrossbardEVP, CMO · Jan 25, 2006 – Jan 26, 2016 · Past
Esteban MasudaSr. VP Research · Oct 10, 2016 – Nov 18, 2019 · Past
Joseph LasagaSr.VP Bus.Dev.Alliance Mgmt. · Oct 10, 2016 – Nov 18, 2019 · Past
Lisa RojkjaerEVP, Chief Medical Officer · Since at least Mar 27, 2024
Raul R. RodriguezPresident and Chief Executive Officer · Since at least Jan 26, 2016
Raymond J FureyEVP, GC, CCO & Corp Sec · Since at least Jan 23, 2024
Robin D G CooperSr. V.P. Pharmaceutical Scs. · Jan 25, 2006 – Jan 31, 2008 · Past
Walter H. MoosDirector · Since at least May 31, 2006

Open People

Log in to ask 6ix AI your own questions about Rigel Pharmaceuticals, Inc.